Glomus Jugulare Tumor
New glomus jugulare tumor research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), radiation approaches (including Gamma Knife) were repeatedly linked to high tumor control in routine care, while surgery reports highlighted nerve-risk tradeoffs and imaging refinements. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Radiation tumor control. Evidence broadened from Gamma Knife to multi-technique radiotherapy series.
- Gamma Knife outcomes. Pooled evidence added side-effect rates and planning-related failure patterns.
- Surgery tradeoffs. Reports clarified independence after surgery alongside advanced-tumor complication risks.
- Imaging for planning. Imaging work moved from mapping extent to refining radiosurgery targets.
- PRRT case. A new non-surgical option was illustrated in one inoperable case.
New
September 2026
- Tumor control. In adults, radiation was linked to high local tumor control.
- Radiation side effects. In one series, no severe radiation side effects were reported.
- PRRT case report. One PRRT case had stable scans and some symptom improvement.
August 2026
- Second surgery. The tumor returned after surgery and needed a larger operation.
- PET/CT monitoring. PET/CT imaging showed a strong signal at the tumor site.
- SDHD gene change. An inherited SDHD variant was tied to recurrence in one case.
July 2026
- Tumor growth control. Follow-up scans often showed tumors did not grow.
- Nerve and hearing changes. A minority had new nerve problems or worse hearing.
- MRI planning detail. Higher-detail MRI can change the target outline for planning.
- Multiple tumors risk. Some people have several tumors, suggesting possible inherited risk.
June 2026
- After-surgery function. Many people had good day-to-day function about a year later.
- Facial nerve injury. Facial nerve injury was reported mainly in advanced tumors.
- Tumor return risk. Some tumors came back or kept growing after treatment.
May 2026
- Gamma Knife results. One session often kept the tumor and symptoms stable.
- Outcome differences. In one review, younger age was linked to lower tumor control.
- Recurrence without MRI. CT and PET DOTA-TATE helped support recurrence when MRI was not possible.
- Blood pressure spike. A rare hormone-secreting tumor caused severe high blood pressure during embolization.
March 2026
- Ear-canal surgery. A small series reported full removal, with hearing often improving.
- Eardrum hole risk. Some patients had an eardrum hole that was later repaired.
- Recurrence follow-up. No recurrences were reported over 1 to 4 years.
January 2026
- Tumor extent on MRI. One contrast MRI sequence matched surgeons on tumor extent.
- Carotid artery involvement. MRI plus CT may better show internal carotid artery involvement.
- Radiotherapy and follow-up. One case used planned radiotherapy with ongoing surveillance.
- Metanephrine blood test. High blood metanephrines suggested a hormone-active tumor.
Get the monthly update by email
Subscribe here to receive an email when a new monthly glomus jugulare tumor update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).